Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBS02: Terbutaline Sulfate PK/PD in Asthma
NCT04973345Phase 3Withdrawn
- Sponsor
- Kanecia Obie Zimmerman
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of terbutaline in asthma (5 arms), sponsored by Kanecia Obie Zimmerman. Primary endpoints: Maximum concentration, Time to Maximum Concentration at 6 hours and 6 more. Planned start Jul 2023; status: withdrawn.
02
Drugs
terbutaline
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04973345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973345.